Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1849193 (PSS)
 2,978 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tamsulosin (0.2 mg) and finasteride (5 mg) once daily for 24 weeks were compared in a single-blind, randomized study as initial treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in 205 Korean patients. Symptom and quality of life (QOL) assessment by the International Prostatic Symptom Score (I-PSS), maximum urinary flow rate (Qmax) and adverse events were analysed at 4 weeks and 24 weeks. On intention-to-treat analysis, both drugs showed similar efficacy at endpoint (decreased I-PSS, increased Qmax and improved QOL score; 34.7%, 23.9% and 34.1% for tamsulosin, and 30.5%, 22.2% and 23.1% for finasteride, respectively). However, tamsulosin produced significant improvements in I-PSS and Qmax at 4 weeks compared with finasteride (17.6% versus 10.0% and 10.9% versus 3.1%, respectively), and a superior QOL score improvement during the study. Adverse events were observed significantly more frequently among finasteride than tamsulosin patients (23 versus four). Both were equally effective in long-term treatment of urinary outflow obstruction symptoms associated with BPH in Korean patients, but tamsulosin was more effective for short-term treatment, with a better safety profile.
 ...
PMID:Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. 1252 85

We determined the clinical efficacy of a loading dose of tamsulosin (0.2-0.3 mg) in patients with benign prostate hyperplasia (BPH). Tamsulosin was administered at a dose of 0.3 mg to 26 patients with BPH and moderate or severe urinary disturbance, as determined on the basis of the international prostate symptom score (I-PSS) and quality of life (QOL) severity. The I-PSS and QOL index were calculated before and at the end of the 12-week administration period. The total I-PSS and QOL index were significantly decreased at 12 weeks compared with the baseline (p=0.003, and p=0.011, respectively). Significant differences were observed in the changes in 3 I-PSS items (stream, p=0.042 ; nocturia, p=0.012 ; urgency, p=0.003). On the basis of these findings, we conclude that the administration of 0.3 mg tamsulosin to patients with BPH improves the scores of objective indexes, and may specifically ameliorate urinary storage symptoms.
 ...
PMID:[Clinical effects of increase in the loading dose of tamsulosin (from 0.2 mg to 0.3 mg) on urinary disturbance associated with benign prostate hyperplasia]. 2061 Sep 19